NewsBenzingaAlpha Tau Medical riceve l’approvazione della FDA per il supplemento all’esenzione per dispositivo sperimentale per ampliare il suo studio REGAIN negli Stati Uniti Alpha Tau Medical riceve l’approvazione della FDA per il supplemento all’esenzione per dispositivo sperimentale per ampliare il suo studio REGAIN negli Stati Uniti Benzinga 2026.10.19 12:35 (GMT+0) Open on Benzinga Other news B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244 Voltus, Google Expand Agreement To Construct 1 GW Virtual Power Plant In PJM Grid B of A Securities Maintains Buy on Meta Platforms, Raises Price Target to $845 Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026 B of A Securities Maintains Buy on SpaceX, Raises Price Target to $275 Bread Financial Holdings Sees FY2026 Sales $4.037B vs $4.024B Est
Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026
